Hereβs the detailed profile for Delamanid Tablet 50 mg π
π Delamanid Tablet 50 mg
π Description:
- Delamanid is a new-generation antituberculosis drug.
- Belongs to the class of nitroimidazole derivatives.
- It works by inhibiting mycolic acid synthesis in Mycobacterium tuberculosis, which is essential for bacterial cell wall formation.
- Mainly used for multi-drug resistant tuberculosis (MDR-TB).
π Prescription / Indications:
- Treatment of pulmonary MDR-TB in adults and children (β₯6 years, β₯20 kg body weight), as part of combination therapy with other effective anti-TB drugs.
- Not used as monotherapy β always combined with at least 3β4 other effective anti-TB drugs.
πΏ Nature / Drug Class:
- Antimycobacterial agent
- Nitroimidazole class
β Advantages:
- Active against drug-resistant TB strains.
- Helps in reducing bacterial load faster when combined with other drugs.
- Improves treatment success rate in MDR-TB patients.
- Can be used in both adults and children β₯6 years (with weight restrictions).
β οΈ Precautions:
Contraindications:
- Known hypersensitivity to delamanid or excipients.
Caution in:
- QT prolongation (cardiac conduction disorder) β risk of arrhythmia.
- Electrolyte disturbances (low potassium, magnesium).
- Severe liver disease.
- Concomitant use with other QT-prolonging drugs (e.g., moxifloxacin, clofazimine).
Adverse Effects:
- QT interval prolongation (dose-related).
- GI upset β nausea, vomiting, abdominal pain.
- Headache, dizziness.
- Hypokalemia.
π Dosage (Adults):
- 100 mg twice daily (total 200 mg/day) for 24 weeks, with food.
- In children (β₯6 years, β₯20 kg): 50 mg twice daily (total 100 mg/day).
- Must be part of a full MDR-TB regimen.
π¦ Common Packaging:
- Tablets of 50 mg (usually in blister strips or bottles).
βοΈ Storage:
- Store below 25Β°C, protected from light and moisture.
- Keep out of reach of children.

